Kazakou, Paraskevi
Tzanetakos, Dimitrios
Vakrakou, Aigli G.
Tzartos, John S.
Evangelopoulos, Μaria-Eleptheria
Anagnostouli, Maria
Stathopoulos, Panos
Kassi, Georgia N.
Stefanis, Leonidas
Kilidireas, Constantinos
Zapanti, Evangelia
Funding for this research was provided by:
University of Athens
Article History
Received: 4 October 2022
Accepted: 20 December 2022
First Online: 15 January 2023
Declarations
:
: Financial interests: PK, AGV, GNK, and EZ have no financial interests to disclose. DT has received travel grants and consulting fees from Roche, Teva, Sanofi-Genzyme, Novartis, and Genesis Pharm. JST has received travel grants and fees for advisory boards from Sanofi-Genzyme, Genesis Pharma, Teva, and Novartis. M-E E has received travel grants and consulting fees from Biogen, Roche, Teva, Genzyme, and Merk. MA has served on scientific advisory boards, has been travel funded by a commercial entity; has received honoraria for speaking engagements and commercial research support from Biogen, Novartis, Sanofi, Teva, Merk-Serono, and Roche. PS has received travel grants from Sanofi and Roche, consulting fees from Imcyse, and support and research funding by the Onassis Foundation. LS is the site investigator in the trials MUSETTE (BN42082) and GAVOTTE (BN42083), sponsored by F. Hoffmann La-Roche Ltd. CK has received grants and honoraria from Bayer, Biogen, Genesis Pharma, Merck-Serono, Novartis, Sanofi-Genzyme, and Teva. Non-financial interests: none.
: Written approval has been obtained from the ethics committee of Eginition Hospital and Alexandra Hospital. Informed written consent to participate was obtained by all participants.